ACHE and early-onset autosomal dominant Alzheimer disease: Galantamine is a centrally acting AChE inhibitor that has been FDA approved to treat the cognitive impairment in patients with Alzheimer’s disease in the United States for more than a decade (Hampel et al., 2018).